Armistice Capital’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Armistice Capital’s Portfolio ATXI Stock Details ATXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-115,000	Closed	-$286K	–	310
2024 Q3	$286K	Buy	115,000 +40,000	+53%	+$115K	﹤0.01%	206
2024 Q2	$263K	Buy	+75,000	New	+$436K	﹤0.01%	195

Other funds holding ATXI

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Armistice Capital's ATXI Position: Q4 2024 in Review

Armistice Capital sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q4 2024, closing a stake of 115,000 shares — an estimated $286K sold.

Armistice Capital first reported a position in ATXI in Q2 2024 and held it in 2 quarters. The position peaked at $286K in Q3 2024. 7 funds tracked by Wall St. Rank hold ATXI as of Q4 2024.

Armistice Capital reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Armistice Capital sold 115,000 Avenue Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $286K.
Armistice Capital first reported a position in Avenue Therapeutics, Inc. Common Stock in Q2 2024 and held it in 2 quarters.
Armistice Capital's Avenue Therapeutics, Inc. Common Stock position peaked at $286K in Q3 2024.
7 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.